The advance, described in next month's issue of Nature Biotechnology, could lead to more accurate
screening of organ donors and identification of genetic targets for new drugs.
Roopam Asthana, director and CEO, Liberty Videocon General Insurance, has said that this plan covers expenses incurred towards
donor's
screening and treatment for harvesting
of the
organ donated.